However, therapeutic success will require precision approaches that account for differences in metabolic programming among tumor cells and immune subsets, careful selection of molecular targets (e.g., LDHA, MCT1, GPR81), and strategies to minimize potential adverse effects on nonmalignant tissues. Here, SLC16A1 is linked to neoplasm.